Prognostic value of baseline alkaline phosphatase of 177Lu‐PSMA radioligand therapy in metastatic castration‐resistant prostate cancer: A systematic review and meta‐analysis

Tianhe Zhang, Wuxue Li, Haiyang Wei, Zhiheng Huang, Junkai Yang, Hanyi Zeng, Zhiyong Zhou and Xinghua Zhao

PLOS ONE, 2024, vol. 19, issue 12, 1-12

Abstract: Background: Current studies have shown inconsistent results regarding the impact of baseline alkaline phosphatase (ALP) levels on the prognosis of metastatic castration-resistant prostate cancer (mCRPC) patients who undergo 177Lu-prostate-specific membrane antigen (PSMA) radioligand therapy (PRLT). Therefore, a comprehensive meta-analysis is needed to clarify the implications. Methods: This study was carried out in full compliance with the PRISMA protocol 2020, and a comprehensive search was conducted through PubMed, Web of Science, and Embase for published literature up to April 1st, 2024. Random-effects models were used to assess the correlation between baseline ALP and overall survival (OS) or progression-free survival (PFS) of mCRPC patients treated with 177Lu-PRLT, with a significance level set at α = 0.05. Results: A total of 12 articles were included in this study. The pooled effect estimates for baseline ALP and OS were 1.134 (95% CI: 1.035–1.245), I2 = 78.7%, P

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0307826 (text/html)
https://journals.plos.org/plosone/article/file?id= ... 07826&type=printable (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:plo:pone00:0307826

DOI: 10.1371/journal.pone.0307826

Access Statistics for this article

More articles in PLOS ONE from Public Library of Science
Bibliographic data for series maintained by plosone ().